BridgeBio Oncology Therapeutics (BBOT)
Kanchan Singh is a highly experienced scientist with a robust background in pre-clinical research, particularly in oncology and biochemistry. Currently serving as a Senior Scientist at BridgeBio Oncology Therapeutics, Kanchan previously held the position of Scientist at BridgeBio and Research Scientist at Rain Therapeutics, where the focus included developing and validating assays for drug testing. Kanchan's prior roles at The University of Texas Health Science Center involved significant contributions to NCI-funded projects and innovative research on pancreatic cancer. Early career experiences include postdoctoral positions at the University of Houston and Central Food Technological Research Institute, along with a PhD in pesticide detection and removal. Kanchan holds a Master’s degree in Biochemistry and is also a PhD graduate in Biotechnology from the University of Mysore.
This person is not in any teams
BridgeBio Oncology Therapeutics (BBOT)
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.